Skip to main content
OpenTrials

Clinical trial condition

Hyperoxaluria

Explore clinical trials studying Hyperoxaluria. Study availability and eligibility vary by location and protocol.

16 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Hyperoxaluria trial results

Recruiting

Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)

NCT06839235

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, +13 more
Locations
  • Mayo Clinic Rochester, Minnesota, United States
  • Nucleus Network Saint Paul, Minnesota, United States
  • Hospices Civils de Lyon- Hôpital Femmes Mères Enfants Lyon, France
  • Kindernierenzentrum Bonn Bonn, Germany
View Trial Details
Completed

Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

NCT05001269

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, +17 more
Locations
  • Clinical Research Site Rochester, Minnesota, United States
  • Clinical Research Site Hamilton, Ontario, Canada
  • Clinical Trial Site Bonn, Germany
  • Clinical Research Site Heidelberg, Germany
View all 13 locations
View Trial Details
Completed

Baby Detect : Genomic Newborn Screening

NCT05687474

Conditions
3-Hydroxy 3-Methyl Glutaric Aciduria, 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency, 3-Hydroxy-3-Methylglutaryl-CoA Synthase 2 Deficiency, +368 more
Locations
  • CRMN, Hôpital La Citadelle Liège, Wallonia, Belgium
View Trial Details
Completed

Natural History of Patients With PH3 and a History of Stone Events

NCT04542590

Conditions
Calcinosis, Calcium Metabolism Disorders, Calculi, +22 more
Locations
  • Clinical Trial Site Boston, Massachusetts, United States
  • Clinical Trial Site New York, United States
  • Clinical Trial Site Toronto, Ontario, Canada
  • Clinical Trial Site Heidelberg, Germany
View Trial Details
Completed

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

NCT04555486

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, +12 more
Locations
  • Clinical Trial Site Boston, Massachusetts, United States
  • Clinical Trial Site Rochester, Minnesota, United States
  • Clinical Trial Site New York, United States
  • Clinical Trial Site Bonn, Germany
View Trial Details
Completed

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

NCT03392896

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, +12 more
Locations
  • Boston Children's Hospital Boston, Massachusetts, United States
  • Centre d'Investigation Clinique - CIC 1407 - Hospices Civils de Lyon Bron, France
  • Universitätsklinikum Bonn-Institut für Klinische Chemie und Klinische Pharmakologie Bonn, Germany
  • University of Amsterdam Amsterdam, Netherlands
View Trial Details
Completed

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

NCT03681184

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, +13 more
Locations
  • Clinical Trial Site San Diego, California, United States
  • Clinical Trial Site Jacksonville, Florida, United States
  • Clinical Trial Site Rochester, Minnesota, United States
  • Clinical Trial Site New York, United States
View all 17 locations
View Trial Details
Completed

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

NCT03847909

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, +16 more
Locations
  • Clinical Trial Site San Francisco, California, United States
  • Clinical Trial Site Boston, Massachusetts, United States
  • Clinical Trial Site Rochester, Minnesota, United States
  • Clinical Trial Site New York, United States
View all 28 locations
View Trial Details

Related conditions